Summary & Overview
HCPCS A9602: Fluorodopa F-18, Diagnostic, per Millicurie
HCPCS Level II code A9602 designates fluorodopa F-18 supplied for diagnostic use and billed per millicurie. Fluorodopa F-18 is a PET radiopharmaceutical used in diagnostic imaging to evaluate dopaminergic function and related neurologic conditions; accurate coding affects billing, utilization tracking, and access to specialized imaging services nationwide. This analysis covers major national payers including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare to provide a national perspective on coverage and reimbursement practices.
Readers will find a concise overview of what the code represents, the typical clinical and service settings where it is used, and which payers are included in the review. The publication summarizes available benchmarks and policy context relevant to radiopharmaceutical billing, highlights common billing considerations for per-millicurie radiotracers, and outlines areas where payers and Medicare may apply specific coverage rules or prior authorization processes. Data not provided in the input are noted where applicable. The focus is national policy and billing context rather than state-specific rules or clinical recommendations.
Billing Code Overview
HCPCS Level II code A9602 represents Fluorodopa F-18, diagnostic, billed per millicurie. This code is used for the radiopharmaceutical agent fluorodopa labeled with fluorine-18 when supplied and billed on a per-millicurie basis.
-
Service type: Diagnostic nuclear medicine radiopharmaceutical administration (radiotracer for PET imaging)
-
Typical site of service: Outpatient imaging centers and hospital outpatient departments where positron emission tomography (PET) studies are performed
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 60-year-old referred for evaluation of suspected Parkinsonian syndromes or to differentiate Parkinson disease from atypical parkinsonism or essential tremor. The patient presents to an outpatient nuclear medicine or PET center after neurology consultation. The clinical workflow: the ordering neurologist documents indication and relevant history; the PET radiopharmacy dispenses A9602 (fluorodopa F‑18) measured per millicurie and performs quality control; the patient arrives fasting or per local PET prep, IV access is established, and medication adjustments (e.g., withholding certain dopaminergic agents) are confirmed. The radiotracer A9602 is administered intravenously, PET imaging of the brain is performed per protocol with attenuation correction and image reconstruction. Images are interpreted by a nuclear medicine physician or neuroradiologist who provides a diagnostic report comparing striatal uptake patterns to normal studies and correlates with clinical impression. Final report and imaging are routed to the referring neurologist for care decisions such as diagnosis clarification and treatment planning.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier; standard billing | Use on routine claims when no special circumstances apply |